• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 4, 2021

View Archived Issues
Amgen headquarters

Amgen buying Five Prime in $1.9B bid to bolster oncology portfolio, expand Asia reach

Lured by what Amgen Inc. CEO Bob Bradway called a "compelling opportunity" to strengthen the Thousand Oaks, Calif.-based company's oncology portfolio and support its international expansion strategy, Amgen on March 4 moved to buy South San Francisco-based Five Prime Therapeutics Inc. for $38 per share, or about $1.9 billion. Read More

$117M series B provides XTENded runway for Amunix

Amunix Pharmaceuticals Inc. CEO Angie You told BioWorld that her firm has already done most of the optimization with its unique T-cell engager platform, so that the effort now is mostly “about cranking out more INDs.” Read More
Cuba mask and syringe

Cuba’s Soberana 02 SARS-CoV-2 vaccine candidate moves to phase III trials

CAJICA, Colombia – Cuba’s Center for the State Control of Drugs, Equipment and Medical Devices gave the green light March 3 for phase III trials of a domestically developed COVID-19 vaccine candidate, even though very little peer-reviewed information has been published about it. Read More

No surprise: COVID-19 creates backlog for FDA’s foreign drug inspections

From the time it paused inspections of drug manufacturing sites a year ago due to the COVID-19 pandemic, the FDA conducted only three foreign “mission-critical” inspections in fiscal 2020. Those were in Canada, Germany and India, according to a new U.S. Government Accountability Office report. Read More
Microrobotic next to penny

Bionaut lands $20M to develop microscale robots to treat CNS disorders

Bionaut Labs emerged from five years in stealth mode raising $20 million to develop Bionauts, microrobots designed to deliver therapies to treat brain disorders. The financing will support the company’s therapeutic program in glioma through preclinical development and further research and development in Huntington’s disease. Read More
Gavel-and-scales.png

Legal woes continue for ‘pharma bro’ and the company he founded

The so-called pharma bro Martin Shkreli’s trials are far from over. The former hedge fund manager, biopharma CEO and now convicted felon is facing a class action lawsuit led by Blue Cross and Blue Shield. Read More

EC launches Teva antitrust investigation

The European Commission (EC) is investigating whether Teva Pharmaceutical Industries Ltd., of Petah Tikva, Israel, illegally delayed the launch and uptake of competitors to its blockbuster multiple sclerosis (MS) drug, Copaxone (glatiramer acetate). Read More

FDA guidance addresses COVID-19 supply constraints

The latest global regulatory news, changes and updates affecting biopharma, including: Australia eases substitution requirements; Guidance details fast-tracking modified vaccines. Read More
Neuropathic pain

Macrophages dampen neuropathic pain

BioWorld looks at translational medicine, including: Collagen means well in pancreatic cancer; Astrocytes are more inflammatory in bipolar disease. Read More

Appointments and advancements for March 4, 2021

New hires and promotions in the biopharma industry, including: Apnimed, Dyne, Egenesis, Fulcrum, Neoimmunetech, Sanofi, Solid. Read More

Earnings for March 4, 2021

Quarterly snapshots from biopharma companies with marketed products, including: Amryt, Chi-Med, Pharming, Vine. Read More

Financings for March 4, 2021

Biopharmas raising money in public or private financings, including: Blossomhill, Elastrin, Onkure, Radius, Salarius. Read More

In the clinic for March 4, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Allarity, Apollomics, Cyclo, Dicerna, Diamyd, Dnatrix, Galapagos, Landos, Lilly, Mallinckrodt, Provention, Ridgeback, Roche, TFF, VBL, Ysopia. Read More

Other news to note for March 4, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Akari, Aptamer, Arch, Astrazeneca, Autifony, Bellicum, Biogen, Boehringer, Claritas, Conserv, Curevac, Dicerna, Etherna, Foresee, Intas, GC, Hookipa, Juvenescence, Lipocine, Lumos, Merck, Mitsubishi Tanabe, Moderna, Novartis, Oncology Pharma, Pandion, Portage, Roche Silo, Sunshine, Therapeutic Solutions, Tonix. Read More

Regulatory actions for March 4, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Kronos, Nervgen, Nicox, Novadip, Ocumension, Pfizer, RDIF, Regeneron, Sanofi. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Stock merger illustration

    Biontech’s $1.25B Curevac buyout removes mRNA lawsuit uncertainty

    BioWorld
    Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its adversary, Curevac NV, through an...
  • Multiple myeloma illustration

    Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset

    BioWorld
    Cullinan Therapeutics Inc. swept up ex-China rights to a multiple myeloma-targeting BCMAxCD3 bispecific T-cell engager (BiTE) velinotamig from Chongqing Genrix...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe